The JV between Boehringer-Ingelheim and Shanghai Zhangjiang Bio-Pharmaceutical Base Development Co. which offers also contract production of biologics for Chinese companies will start full production by 2017. At present, the plant provides samples for toxicity testing and early clinical studies.
China Bio news release, August 21, 2015